Related references
Note: Only part of the references are listed.AFLIBERCEPT FOR THE TREATMENT OF RETINAL PIGMENT EPITHELIAL DETACHMENTS
Lingmin He et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
Improvement in Vision-Related Function with Intravitreal Aflibercept Data from Phase 3 Studies in Wet Age-Related Macular Degeneration
Mitsuko Yuzawa et al.
OPHTHALMOLOGY (2015)
RESPONSE OF PIGMENT EPITHELIAL DETACHMENTS TO INTRAVITREAL AFLIBERCEPT AMONG PATIENTS WITH TREATMENT-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Geoffrey K. Broadhead et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2015)
Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD
Figen Batioglu et al.
BMC OPHTHALMOLOGY (2015)
Change of therapy from ranibizumab to aflibercept for recurrent or persistent exudative age-related macular degeneration
M. Ziegler et al.
OPHTHALMOLOGE (2015)
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis
Rishi P. Singh et al.
CLINICAL OPHTHALMOLOGY (2015)
Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration
Philip J. Ferrone et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results
D. S. Grewal et al.
EYE (2014)
Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
Heidi Fassnacht-Riederle et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2014)
Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
Magda Gharbiya et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Response to Aflibercept After Frequent Re-treatment With Bevacizumab or Ranibizumab in Eyes With Neovascular AMD
Mariana R. Thorell et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2014)
Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab
K. H. Patel et al.
EYE (2013)
VISUAL AND ANATOMICAL OUTCOMES OF INTRAVITREAL AFLIBERCEPT IN EYES WITH PERSISTENT SUBFOVEAL FLUID DESPITE PREVIOUS TREATMENTS WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Nishant Kumar et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence
Ugo Introini et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2012)
HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Michael A. Singer et al.
OPHTHALMOLOGY (2012)
One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration
S. Arora et al.
EYE (2011)
Quantification of the Therapeutic Response of Intraretinal, Subretinal, and Subpigment Epithelial Compartments in Exudative AMD during Anti-VEGF Therapy
Isabelle Golbaz et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Effect of intravitreal ranibizumab in avascular pigment epithelial detachment
M. Ritter et al.
EYE (2010)
LONG-TERM FOLLOW-UP FOR TYPE 1 (SUBRETINAL PIGMENT EPITHELIUM) NEOVASCULARIZATION USING A MODIFIED TREAT AND EXTEND'' DOSING REGIMEN OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
Michael Engelbert et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2010)
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
Geeta A. Lalwani et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments
A. Lommatzsch et al.
EYE (2009)
A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration
David S. Boyer et al.
OPHTHALMOLOGY (2009)
TREAT AND EXTEND DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION
Michael Engelbert et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration
Florence Coscas et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2007)
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration
Anne E. Fung et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2007)
Pigment epithelial detachment in the elderly -: Clinical differentiation, natural course and pathogenetic implications
D Pauleikhoff et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2002)
Share Paper
